•  

Start-Up Companies

Bristol Myers Squibb Enters Agreement to Acquire Forbius

TIAP portfolio company Forbius announced on August 24, 2020 that they have entered into an acquisition deal with Bristol Myers Squibb. BMS is adding lead TGF-beta asset to its portfolio. TIAP was one of the earliest investors and partners with Forbius in 2011/12. This is a big win for Forbius CEO Dr. Tikhomirov and the Canadian research and innovation community. Forbius (formerly Formation Biologics) is a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic ... Read more

Zucara Therapeutics Announces US$21M Series A Financing

– Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials – – Series A Financing led by the Perceptive Xontogeny Venture Fund  – TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”). The proceeds from the financing will fund Phase 1 and ... Read more

Fibrocor and Galapagos Sign Expanded Collaboration in Fibrosis

Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel targets in fibrosis, with Galapagos taking an equity stake in Fibrocor. Fibrocor is a privately held Canadian company specializing in the development of tissue-specific therapeutics to treat fibrotic diseases of the kidney, liver, lung and other organs. To date, the company has successfully identified a suite of novel targets in fibrosis through ... Read more

Notch Therapeutics, a new company in the field of gene-modified T cell therapy

Toronto, ON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that creates allogeneic (donor) gene-edited T cells from stem cells on an industrial scale, efficiently making T cell therapies that are clinically robust and of a consistently high quality. Notch is actively pursuing industry partnerships. The founders of Notch - Sunnybrook Health Sciences Centre, University of Toronto (UoT), Toronto Innovation Acceleration Partners (TIAP) ... Read more

Zealand Pharma Acquires Encycle Therapeutics

Our portfolio company, Encycle Therapeutics, has been acquired by Danish Zealand Pharma. The transaction strengthens the leadership of Zealand Pharma (NASDAQ: ZEAL) in peptide therapeutics and in targeting gastrointestinal diseases with the addition of a pre-clinical, orally-delivered macrocycle peptide (integrin alpha-4-beta-7 inhibitor). Encycle is founded on research coming from University of Toronto - a TIAP member institution. Read more here: http://bit.ly/2W2hH4N   Read more

Triphase Accelerator Enters Partnership with Celgene for Leukemia Therapy

Toronto, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, a Toronto-based drug development company, has entered into a new strategic partnership with Celgene Corporation. The focus of the collaboration will be on a pre-clinical therapeutic developed by the Ontario Institute for Cancer Research (OICR) for the treatment of leukemia and other blood cancers, specifically targeting the WDR5 protein. Under the terms of the agreement, Celgene has the option to acquire TRPH-395 from Triphase Accelerator. Celgene will pay an upfront amount of ... Read more

Fibrocor Therapeutics enters deal with Galapagos NV

Toronto, ON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics, a privately held Canadian company, and Galapagos NV, a Belgo-Dutch pharmaceutical research company, have announced the formation of a partnership for the development of therapeutics to treat fibrotic diseases of the kidney and other organs. In 2017 MaRS Innovation founded, and subsequently seed-funded, Fibrocor. The company is based on research from two of MaRS Innovation’s Member institutions, St. Michael’s Hospital and Sinai Health Systems – specifically, from the labs of Drs. Richard ... Read more

Launch of Bright Angel Therapeutics

New York, NY and Toronto Canada, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Schrödinger, Inc., a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods, and MaRS Innovation, a non-profit organization supporting the commercialization of research breakthroughs from Toronto’s leading academic institutions, today announced the launch of Bright Angel Therapeutics. The new Toronto-based company is focused on the development of novel therapeutics for treatment of drug-resistant and life-threatening fungal infections. Bright Angel’s first program is based on foundational research from ... Read more

Fibrocor Therapeutics Appoints Its First CEO

Toronto, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics (Fibrocor) announced today that Mark Steedman has been appointed as its first president and CEO, and will serve as a member of Fibrocor’s board of directors. Mr. Steedman is the co-founder of Interface Biologics where he most recently served as VP, Business Development. He was responsible for all start-up operations including financing and business development up to Series A totaling $13M, and was instrumental in early transactions with large multinational corporations, which ultimately led ... Read more

Encycle Therapeutics announces discovery collaboration with Pfizer Inc.

TORONTO, November 1, 2017 – Encycle Therapeutics (“Encycle”), a Toronto-based drug discovery company built on a unique chemistry that enables the synthesis of a new type of constrained peptide called “nacellins,” today announced a research collaboration with Pfizer Inc. (“Pfizer”) (NYSE: PFE). Encycle and Pfizer will partner to optimize certain nacellins, which were previously identified by Pfizer during a screening of Encycle’s proprietary nacellin library, that act on an undisclosed therapeutic target. Nacellins are a type of peptide macrocycle that can often exhibit ... Read more
Page 1 of 2312345...1020...Last »